Clinicopathological characteristics and PRAME/PD-L1 expression in urothelial neoplasms of patients younger than 40 years of age

Urothelial neoplasms are uncommon in young patients, and clinicopathological, prognostic and immunohistochemical data in this population remain limited. This study aimed to evaluate PRAME and PD-L1 expression in urothelial neoplasms diagnosed in patients younger than 40 years and to assess differences in expression according to clinicopathological features. A total of 66 urothelial neoplasms diagnosed between 2008 and 2023 in patients younger than 40 years were retrospectively reviewed. PRAME and PD-L1 (SP263 and 22C3 clones) immunohistochemistry was performed on 52 specimens from 46 patients. PRAME expression was evaluated using raw percentage and combined-score analyses. For comparison between the two PD-L1 clones, tumor proportion score (TPS) and immune cell score (ICS) were assessed for both SP263 and 22C3, while combined positive score (CPS) was additionally calculated for 22C3. The mean age at diagnosis was 31.5 ± 7.4 years, and most patients were male (75.8%). Recurrence occurred in 22.7% of patients. After excluding urothelial papillomas ( n = 9), 80.7% (46/57) of urothelial neoplasms were low-grade group. PRAME expression was identified in 73.9% of 46 patients. No statistically significant difference was found in the raw PRAME percentage distributions of the examined clinicopathological variables ( p > 0.05). Although there was no progressive trend with increasing tumor grade, a statistically significant association was found between the PRAME combined score categories and the tumor grade categories and diagnosis categories ( p = 0.013 and p = 0.033, respectively). PD-L1 expression was predominantly negative or low in the comparative TPS and ICS assessments with both SP263 and 22C3, and no patient had a 22C3 CPS ≥ 10. To our knowledge, this is the first study to evaluate both PRAME and PD-L1 expression in urothelial neoplasms occurring in patients younger than 40 years. These findings add to the limited data on biomarker expression in this rare patient population; however, the clinicopathological relevance of PRAME and PD-L1 remains incompletely characterized and requires further evaluation in larger studies.

Authors

Institutions

Publication Details

Journal
Diagnostic Pathology
Published
2026-11-13
DOI
https://doi.org/10.1186/s13000-026-01873-w
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinicopathological characteristics and PRAME/PD-L1 expression in urothelial neoplasms of patients younger than 40 years of age

Evrim Önder, Merve Oğuz Dağdaş
Diagnostic Pathology
Bladder and Urothelial Cancer Treatments
article

Clinicopathological characteristics and PRAME/PD-L1 expression in urothelial neoplasms of patients younger than 40 years of age

Evrim Önder, Merve Oğuz Dağdaş
article en

Abstract

Urothelial neoplasms are uncommon in young patients, and clinicopathological, prognostic and immunohistochemical data in this population remain limited. This study aimed to evaluate PRAME and PD-L1 expression in urothelial neoplasms diagnosed in patients younger than 40 years and to assess differences in expression according to clinicopathological features. A total of 66 urothelial neoplasms diagnosed between 2008 and 2023 in patients younger than 40 years were retrospectively reviewed. PRAME and PD-L1 (SP263 and 22C3 clones) immunohistochemistry was performed on 52 specimens from 46 patients. PRAME expression was evaluated using raw percentage and combined-score analyses. For comparison between the two PD-L1 clones, tumor proportion score (TPS) and immune cell score (ICS) were assessed for both SP263 and 22C3, while combined positive score (CPS) was additionally calculated for 22C3. The mean age at diagnosis was 31.5 ± 7.4 years, and most patients were male (75.8%). Recurrence occurred in 22.7% of patients. After excluding urothelial papillomas ( n = 9), 80.7% (46/57) of urothelial neoplasms were low-grade group. PRAME expression was identified in 73.9% of 46 patients. No statistically significant difference was found in the raw PRAME percentage distributions of the examined clinicopathological variables ( p > 0.05). Although there was no progressive trend with increasing tumor grade, a statistically significant association was found between the PRAME combined score categories and the tumor grade categories and diagnosis categories ( p = 0.013 and p = 0.033, respectively). PD-L1 expression was predominantly negative or low in the comparative TPS and ICS assessments with both SP263 and 22C3, and no patient had a 22C3 CPS ≥ 10. To our knowledge, this is the first study to evaluate both PRAME and PD-L1 expression in urothelial neoplasms occurring in patients younger than 40 years. These findings add to the limited data on biomarker expression in this rare patient population; however, the clinicopathological relevance of PRAME and PD-L1 remains incompletely characterized and requires further evaluation in larger studies.

Diagnostic Pathology
Ankara University (TR), Ankara Etlik City Hospital (TR)
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon